TY  - BOOK
AU  - Shorr, Andrew F
TI  - Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial
SN  - 1369-6998
PY  - 2016///
KW  - *Antifungal Agents/tu [Therapeutic Use]
KW  - *Length of Stay/ec [Economics]
KW  - *Mycoses/dt [Drug Therapy]
KW  - *Mycoses/ec [Economics]
KW  - *Nitriles/tu [Therapeutic Use]
KW  - *Pyridines/tu [Therapeutic Use]
KW  - *Triazoles/tu [Therapeutic Use]
KW  - *Voriconazole/tu [Therapeutic Use]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antifungal Agents/ec [Economics]
KW  - Aspergillosis/dt [Drug Therapy]
KW  - Aspergillosis/ec [Economics]
KW  - Body Mass Index
KW  - Double-Blind Method
KW  - Female
KW  - Glomerular Filtration Rate
KW  - Hospital Charges/sn [Statistics & Numerical Data]
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Nitriles/ec [Economics]
KW  - Pyridines/ec [Economics]
KW  - Triazoles/ec [Economics]
KW  - Voriconazole/ec [Economics]
KW  - Young Adult=520  \\
KW  - OBJECTIVE: In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other filamentous fungi. This analysis assessed whether hospital resource utilization was different between patients treated with isavuconazole vs voriconazole in SECURE
KW  - MedStar Washington Hospital Center
KW  - Medicine/Pulmonary-Critical Care
KW  - Journal Article
N2  - CONCLUSIONS: Isavuconazole may reduce hospital LOS in certain subgroups of patients with IMD, especially those with moderate-to-severe renal impairment; LIMITATIONS: As the patient subgroups analyzed were small, sub-group findings should be interpreted with caution in light of the lack of statistical significance for each sub-group-by-treatment interaction; METHODS: The analysis population comprised adults with proven/probable/possible IMD enrolled in SECURE. The primary endpoint was hospital length of stay (LOS) in the overall trial population. Patients were also stratified by estimated glomerular filtration rate-modification of diet in renal disease category (< 60mL/min/1.73 m(2) [moderate-to-severe impairment] and >60mL/min/1.73 m(2) [mild or no impairment]), body mass index (BMI; <25, >25-<30, and >30kg/m(2)), and age (<45, >45-<65, and >65 years); RESULTS: Data from 516 patients (258 per arm) were evaluated. Overall, median LOS was not statistically significantly different between the isavuconazole (15.0 days) and voriconazole (16.0 days; p=0.607) arms. Median LOS was statistically significantly shorter in patients with moderate-to-severe renal impairment treated with isavuconazole (9.0 days) vs voriconazole (19.0 days; hazard ratio [HR]: 3.44; 95% confidence interval [CI]=1.51-7.83). Median LOS was shorter, but not significantly, in patients with a BMI >30kg/m(2) (isavuconazole 13.5 days vs voriconazole 22 days; HR=1.57; 95% CI=0.70-3.52) or aged >65 years (isavuconazole 15.0 days vs voriconazole 20.0 days; HR=1.37; 95% CI=0.87-2.16)
UR  - https://dx.doi.org/10.3111/13696998.2016.1164175
ER  -